Study finds genetic prostate cancer screening feasible

By LabPulse.com staff writers

June 1, 2020 -- Research presented at the recent American Society of Clinical Oncology (ASCO) virtual conference has shown that genetic screening for prostate cancer is feasible and helps spot disease in asymptomatic men.

A group led by Dr. Rosalind Eeles of the Institute of Cancer Research in London and the Royal Marsden National Health Service (NHS) Foundation Trust evaluated a genetic test that identified DNA changes suggesting increased risk of prostate cancer. They found that screening was not only safe and feasible, but it identified new cancers in more than a third of asymptomatic men and could improve upon prostate-specific antigen (PSA) testing.

"Genetic screening could detect potentially aggressive cancers more effectively than PSA testing -- which is controversial because of its high rates of overdiagnosis," Eeles said in a statement released by the institute.

Eeles' group collected saliva samples from 307 white men and assessed the samples for 130 genetic changes that could boost the men's risk of developing prostate cancer. Each man was assigned an overall prostate cancer risk score. Twenty-six of the 307 patients were selected for further screening; of these 18 underwent magnetic resonance imaging (MRI) scans and biopsy. Seven of the 18 were diagnosed with prostate cancer.

"We were able to identify prostate cancers in over a third of the 18 apparently healthy men who we found to have the highest levels of inherited risk," Eeles said in the statement.

The investigators also assessed how aggressive the cancers identified were, finding that all seven had a mean PSA score of 1.8, which can be safely managed through active surveillance.

"We showed that genetic 'barcoding' of men can safely and effectively identify those at the highest level of risk for prostate cancer, so they can be targeted for follow-up checks," she said.

The researchers plan to conduct another study that will recruit 5,000 patients who will undergo the genetic test.

Less prostate-specific antigen testing linked with more advanced tumors
Less prostate-specific antigen testing in the wake of guidelines that discouraged use was linked to a drop in diagnosis of early-stage disease and more...
Urine test could reduce unnecessary prostate biopsies
A new urine test developed by U.K. researchers shows promise for reducing unnecessary prostate biopsies, according to a study published online March 9...
Could liquid biopsy replace PSA for prostate cancer?
A liquid biopsy blood test that identifies the earliest genetic changes of prostate cancer has been developed by researchers from the U.K., who believe...
Myriad files companion BRCA test in prostate cancer
Myriad Genetics' BRACAnalysis companion diagnostic for the drug olaparib (Lynparza) is headed for a new indication in prostate cancer, following the filing...
AI seeks role in evaluating prostate biopsies
An investigational artificial intelligence (AI) system demonstrated excellent performance for differentiating benign from cancerous findings in prostate...

Copyright © 2020 LabPulse.com

Last Updated ls 6/1/2020 4:19:03 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email